Perspective: Minimal clinically important difference (MCID) and Alzheimer's disease clinical trials
Abstract The minimum clinically important difference (MCID) is a measure of the minimal clinically relevant change. The MCID represents the smallest difference in score on the measure or domain of interest which patients or clinicians perceive as beneficial or as meaningful decline. The MCID is not...
Saved in:
| Main Author: | Jeffrey Cummings |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.70059 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials
by: J. Scott Andrews, et al.
Published: (2019-01-01) -
Three approaches to determining clinically meaningful benefit on the Cohen‐Mansfield Agitation Inventory in dementia clinical trials for agitation
by: Kathy Y. Liu, et al.
Published: (2025-04-01) -
Assessing clinical meaningfulness in clinical trials for Alzheimer's disease: A U.S. regulatory perspective
by: Teresa Buracchio, et al.
Published: (2025-04-01) -
The minimal clinically important difference changes greatly based on the patient's baseline clinical status
by: Marco Franceschini, et al.
Published: (2025-01-01) -
Incorporating individually defined brain health priorities in clinical trial outcomes: the electronic Person‐Specific Outcome Measure approach in the United States
by: Stina Saunders, et al.
Published: (2025-04-01)